UY25332A1 - Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos - Google Patents

Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos

Info

Publication number
UY25332A1
UY25332A1 UY25332A UY25332A UY25332A1 UY 25332 A1 UY25332 A1 UY 25332A1 UY 25332 A UY25332 A UY 25332A UY 25332 A UY25332 A UY 25332A UY 25332 A1 UY25332 A1 UY 25332A1
Authority
UY
Uruguay
Prior art keywords
alkyl
alkoxy
indol
inflammatory
nr2r3
Prior art date
Application number
UY25332A
Other languages
English (en)
Inventor
Kiyoshi Kawamura
Rodney William Stevens
Kazunari Nakao
Hiroki Koike
Stephane Caron
Chikara Uchida
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to UY25590A priority Critical patent/UY25590A1/es
Publication of UY25332A1 publication Critical patent/UY25332A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención se refiere a indoles 2,3-sustituidos de fórmula (I), en la que: Z es OH, alcoxi, -NR2R3 o un grupo de la fórmula (II) o (III): en las que r es 1, 2, 3 ó 4, Y es un enlace simple, O, S o NR4, y W es OH o -NR2R3; Q se selecciona entre los siguientes: (a) fenilo, (b) un grupo aromático monocíclico de 6 eslabones que contiene uno, dos, tres o cuatro átomo(s) de nitrógeno, (c) un grupo aromático monocíclico de 5 eslabones que contiene un heteroátomo seleccionado entre O, S y N, (d) cicloalquilo, (e) un heterociclo condensado con benceno; R1 es H, alquilo o halo; R2 y R3 son, independientemente, H, OH, alcoxi, alquilo, haloalquilo, NH2 o CN; R4 es H o alquilo; X se selecciona independientemente entre halo, alquilo, haloalquilo, OH, alcoxi, alquiltio, NO2, NH2, di-(alquil)amino, CN, alquilsulfonilo, aminosulfonilo, acetilo, -COOH, -C(O)O-alquilo, alquilsulfonilamino y cicloalquilo; y n es 0, 1, 2, 3 ó 4; y a sales farmacéuticamente aceptables de los mismos. Dichos compuestos son útiles en el tratamiento o alivio del dolor y la inflamación, y de otros trastornos asociados con la inflamación, tales como la artritis. Ej. no limitante: ácido [6-cloro-2-(2-metilbenzoil)-1H-indol-3-il]acético.
UY25332A 1998-01-05 1998-12-31 Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos UY25332A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY25590A UY25590A1 (es) 1998-01-05 1999-06-28 Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9800003 1998-01-05

Publications (1)

Publication Number Publication Date
UY25332A1 true UY25332A1 (es) 2001-01-31

Family

ID=11004645

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25332A UY25332A1 (es) 1998-01-05 1998-12-31 Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos
UY25590A UY25590A1 (es) 1998-01-05 1999-06-28 Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY25590A UY25590A1 (es) 1998-01-05 1999-06-28 Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos

Country Status (39)

Country Link
US (1) US6608070B1 (es)
EP (1) EP1045833B1 (es)
JP (1) JP3347136B2 (es)
KR (1) KR100404054B1 (es)
CN (1) CN1284064A (es)
AP (1) AP869A (es)
AR (1) AR016977A1 (es)
AT (1) ATE308519T1 (es)
AU (1) AU748107B2 (es)
BG (1) BG104643A (es)
BR (1) BR9813124A (es)
CA (1) CA2316863A1 (es)
CO (1) CO4970807A1 (es)
DE (1) DE69832200T2 (es)
DZ (1) DZ2700A1 (es)
EA (1) EA200000614A1 (es)
ES (1) ES2255190T3 (es)
GT (1) GT199800205A (es)
HN (1) HN1997000098A (es)
HR (1) HRP20000454A2 (es)
HU (1) HUP0102922A3 (es)
ID (1) ID24876A (es)
IL (1) IL136885A0 (es)
IS (1) IS5532A (es)
MA (1) MA24736A1 (es)
NO (1) NO20003451L (es)
OA (1) OA11441A (es)
PA (1) PA8466201A1 (es)
PE (1) PE20000055A1 (es)
PL (1) PL341696A1 (es)
SA (1) SA99191299A (es)
SK (1) SK9912000A3 (es)
TN (1) TNSN99001A1 (es)
TR (1) TR200001906T2 (es)
TW (1) TW436482B (es)
UY (2) UY25332A1 (es)
WO (1) WO1999035130A1 (es)
YU (1) YU41600A (es)
ZA (1) ZA9911B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
DE60000556T2 (de) * 1999-07-02 2003-02-13 Pfizer Tetrazolylalkyl-Indolderivate als entzündungshemmende und analgetische Mittel
MXPA00006605A (es) * 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
CA2509881A1 (en) * 2002-12-19 2004-07-08 Elan Pharmaceuticals, Inc. Substituted n-phenyl sulfonamide bradykinin antagonists
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
KR100795462B1 (ko) * 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
KR101419965B1 (ko) 2006-10-17 2014-07-16 스티펠 래버러토리즈, 인코포레이티드 탈라로졸 대사물
US20120022121A1 (en) * 2007-11-29 2012-01-26 Dalton James T Indoles, derivatives and analogs thereof and uses therefor
HUE030263T2 (en) 2010-04-19 2017-04-28 Octeta Therapeutics Llc New synthesis for the preparation of thiazolidinedione compounds
WO2012006474A2 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827328B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP5827326B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP5823514B2 (ja) 2010-07-07 2015-11-25 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
PL2603507T3 (pl) 2010-08-10 2016-12-30 Synteza związków tiazolidynodionu
EP2603498B1 (en) 2010-08-10 2016-11-09 Octeta Therapeutics, LLC Novel synthesis for thiazolidinedione compounds
US10266490B2 (en) * 2012-03-16 2019-04-23 Georgetown University Radioprotector compounds
US9808443B1 (en) 2016-11-28 2017-11-07 King Saud University Cyclooxygenase inhibitors
CN111004121A (zh) * 2019-12-09 2020-04-14 南京杰运医药科技有限公司 一种4-烷氧基乙酰乙酸酯类化合物的制备方法
CN112409281B (zh) * 2020-08-20 2022-11-18 上海大学 (e)-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的合成方法
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2

Also Published As

Publication number Publication date
AU748107B2 (en) 2002-05-30
CN1284064A (zh) 2001-02-14
ID24876A (id) 2000-08-31
NO20003451L (no) 2000-09-01
KR20010033859A (ko) 2001-04-25
EA200000614A1 (ru) 2001-02-26
BR9813124A (pt) 2000-10-10
EP1045833B1 (en) 2005-11-02
TNSN99001A1 (fr) 2005-11-10
HN1997000098A (es) 1998-12-28
SK9912000A3 (en) 2001-11-06
JP3347136B2 (ja) 2002-11-20
PA8466201A1 (es) 2000-09-29
OA11441A (en) 2004-04-27
DE69832200D1 (de) 2005-12-08
PE20000055A1 (es) 2000-02-08
HRP20000454A2 (en) 2001-04-30
KR100404054B1 (ko) 2003-11-01
AP869A (en) 2000-09-04
ATE308519T1 (de) 2005-11-15
CA2316863A1 (en) 1999-07-15
HUP0102922A3 (en) 2003-06-30
MA24736A1 (fr) 1999-10-01
CO4970807A1 (es) 2000-11-07
TW436482B (en) 2001-05-28
PL341696A1 (en) 2001-04-23
HUP0102922A2 (hu) 2001-12-28
IS5532A (is) 2000-06-13
AU1500599A (en) 1999-07-26
IL136885A0 (en) 2001-06-14
ES2255190T3 (es) 2006-06-16
AR016977A1 (es) 2001-08-01
DZ2700A1 (fr) 2003-09-01
BG104643A (bg) 2001-02-28
JP2002500217A (ja) 2002-01-08
NO20003451D0 (no) 2000-07-04
GT199800205A (es) 2000-06-21
UY25590A1 (es) 1999-09-27
SA99191299A (ar) 2005-12-03
YU41600A (sh) 2003-08-29
TR200001906T2 (tr) 2001-01-22
US6608070B1 (en) 2003-08-19
ZA9911B (en) 2000-07-04
EP1045833A1 (en) 2000-10-25
DE69832200T2 (de) 2006-04-20
AP9801423A0 (en) 1998-12-31
WO1999035130A1 (en) 1999-07-15

Similar Documents

Publication Publication Date Title
UY25332A1 (es) Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
PA8487601A1 (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
AR009321A1 (es) Compuestos derivados de 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen y compuestos intermediarios.
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
CR7698A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
HN1998000074A (es) Derivados de macrolidos c-4 sustituidos
PA8486001A1 (es) Composiciones de celecoxib
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
BR9307580A (pt) Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
OA08023A (fr) Nouvelles bis-(4-aminophényl)-sulfones substituées, leur préparation et leur utilisation en tant que médicament.
MX9205123A (es) Derivados de 5-hidroxi-2-pirimidinilmetileno utiles como agentes anti-inflamatorios.
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen
AR029001A1 (es) Derivados de bencil-3,4-metilendioxicinamico y el uso de los mismos para la manufactura de un medicamento
AR038197A1 (es) Acidos 3-(imidazolil)-2-alcoxipropanoicos, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y uso de los mismos en la preparacion de medicamentos
PA8471901A1 (es) Derivados de 2"-desoxi higromicina
AR015130A1 (es) 1,3-dioxolanos 2,4,4-trisubstituidos antimicoticos, su uso para la manufactura de medicamentos, composiciones farmaceuticas que los contienen y procedimiento para preparar estos compuestos.

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20181231